Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Cagol, Matteo (2009) L' immunocomplesso SCCA-IgM come marker prognostico del carcinoma esofago-cardiale. [Tesi di dottorato]

Full text disponibile come:

[img]Documento PDF
Tesi non accessible per motivi correlati alla proprietà intellettuale.
Visibile a: nessuno

693Kb

Abstract (inglese)

Introduction. Esophageal cancer is often diagnosed at an advanced stage, and has a poor prognosis. To date, no biomarkers with high sensitivity and specificity for esophageal carcinoma are available that could be used for early diagnosis.
Aims and Methods. Aim of the study was to evaluate the presence of circulating SCCA-IgM immunocomplexes in the serum of patients diagnosed to have carcinoma of the esophagus and cardia, and to identify possible correlations with clinical and tumor features.
SCCA-IgM levels were measured by ELISA assay (Hepa-IC, Xeptagen S.p.A.) in the serum of 92 untreated patients with squamous cell carcinoma or adenocarcinoma of the esophagus and cardia. Positivity for SCCA-IgM was defined using a cut off level of 120 U/ml. The results obtained were compared to clinical and histological variables correlated to prognosis.
Results. Overall, SCCA-IgM immunocomplexes were positive in the serum of 13/92 patients (14,1%). The percentage of positivity was significantly higher in patients with lower clinical TNM stage (stage 0-1 vs stage 2-3-4: 33,3% vs 9,4%; p= 0,01); a higher percentage of positivity was found also in patients with lower pathological TNM stage, although the difference did not reach statistical significance (stage 0-1 vs stage 2-3-4: 29,4% vs 13,6%; p=0,26). No correlation was found between serum SCCA-IgM level and other clinical and histological variables.
Conclusion. Serum SCCA-IgM immunocomplexes were more frequently found in patients with an early stage cancer of the esophagus and cardia.

Abstract (italiano)

Introduzione. Il carcinoma dell'esofago è spesso diagnosticato in fase avanzata ed ha una prognosi infausta. Attualmente non sono disponibili marcatori di diagnosi precoce con alta sensibilità e specificità .
Scopo dello studio e metodi. Scopo del presente studio è di valutare la presenza dell'immunocomplesso SCCA-IgM nel siero di pazienti affetti da carcinoma esofageo e del cardias al momento della diagnosi e di identificare una eventuale correlazione clinica con diverse caratteristiche della malattia neoplastica.
Mediante metodica ELISA indiretto (Hepa-IC, Xeptagen S.p.A) è stato effettuato il dosaggio sierico dell'immunocomplesso SCCA-IgM in 92 pazienti con diagnosi istologica di carcinoma squamoso o adenocarcinoma dell'esofago e del cardias, al momento della diagnosi, prima di qualsiasi trattamento oncologico. La positività per il dosaggio sierico di SCCA-IgM è stata definita per valori superiori al cut-off di 120 U/ml. I risultati del dosaggio sono stati confrontati con le variabili cliniche e istologiche correlate con la prognosi.
Risultati. 13/92 pazienti (14,1%) sono risultati positivi al dosaggio sierico dell'immunocomplesso SCCA-IgM. La positività è risultata superiore nei pazienti con stadio clinico di malattia più precoce rispetto a quelli in uno stadio clinico più avanzato (stadio 0-1 vs stadio 2-3-4: 33,3% vs 9,4 p= 0,01) e nei pazienti con stadio patologico più precoce rispetto a quelli con stadio patologico più avanzato (stadio 0-1 vs stadio 2-3-4: 29.4% vs 13.6%; p=0.26). Non si è riscontrata alcuna differenza tra i livelli sierici di SCCA-IgM e le altre variabili cliniche ed istologiche studiate.
Conclusione. L'immunocomplesso SCCA-IgM circolante risulta significativamente piu' presente, al momento della diagnosi, negli stadi iniziali di neoplasia esofago-cardiale.

Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Ruol, Alberto
Dottorato (corsi e scuole):Ciclo 21 > Corsi per il 21simo ciclo > ONCOLOGIA E ONCOLOGIA CHIRURGICA
Data di deposito della tesi:29 Gennaio 2009
Anno di Pubblicazione:Gennaio 2009
Parole chiave (italiano / inglese):Esophageal cancer; immunocomplex; biomarker
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/18 Chirurgia generale
Struttura di riferimento:Dipartimenti > pre 2012 - Dipartimento di Scienze Oncologiche e Chirurgiche
Codice ID:1716
Depositato il:29 Gen 2009
Simple Metadata
Full Metadata
EndNote Format

Bibliografia

I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

1. Issam El Nakadi, Jean-Luc Van Laethem, _Jean-Jacques Houben, Michel Gelin. Squamous Cell Carcinoma of the esophagus: Multimodal Therapy in locally advanced disease.World J Surg. 2002; 26: 72-78 Cerca con Google

2. Fink U, Stein HJ, Siewert JR Multimodal treatment for squamous cell esophageal cancer. World J Surg. 1995; 19: 128 Cerca con Google

3. Collard J.M., Giuli R. Surgical and multimodal approaches to cancer of the esophagus: state of art. Acta Gastroenterologica Belgica. 1999; 62: 272-282. Cerca con Google

4. Herskovic A., Martz K., Al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 1992; 326: 1593-98. Cerca con Google

5. Roussel A., Haegele P., Palliot B. Result of EORTC-GTCCG phase III trial of irradiation vs irradiation and Cisplatin in inoperable esophageal cancer. Proc. Am. Soc. Clin. Oncol. 1994; 13: A538. Cerca con Google

6. Schnirer I., Komani R., Yao J.C., Swisher S., Putnam J., Pisters P., Roth J.A., Ajani J.A. Pilot Study of Cuncurrent 5-Fluorouracil/Paclitaxel Plus Radiotherapy in Patients With Carcinoma of the Esophagus and Gastroesophageal Junction.Am. J. Clin. Oncol. 2001; 24: 91-95 Cerca con Google

7. Araujio C.M., Souhami L., Gil R.A., Carvalho R., Garcia J.A., Froimtchuk M.J., Pinto L.H., Canary P.C. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus.Cancer 1991; 67: 2258-2261. Cerca con Google

8. Tordiglione M., Kalli M., Vavassori V., Luraghi R. Combined modality treatment for esophageal cancer. Tumori 1998; 84: 252-258. Cerca con Google

9. Ancona E., Ruol A., Castoro C., et al. First-line chemotherapy improves the resection rate and lonf-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus. Ann Surg 1997; 226:714-24. Cerca con Google

10. Chiarion-Sileni V, Innocente R, Cavina R, Ruol A, Corti L, Pigozzo J, Del Bianco P, Fumagalli U, Santoro A, Ancona E. Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemother Pharmacol. 2008 Sep 30. Cerca con Google

11. Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States : racial and gender differences by histological type. Scand J Gastroenterol 2002; 37: 1359-65 Cerca con Google

12. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-2150. Cerca con Google

13. Enzinger P.C., Mayer R.J. Esophageal cancer. New Engl. J. Med. 2003; 349: 2241-52. Cerca con Google

14. Ziv Gamliel. Incidence, epidemiology, and etiology of esophageal cancer. Chest Surg. Cl. N. Am. 2000; 10: 441-449. Cerca con Google

15. Cislaghi C, De Carli A, La Vecchia C, et al. Data, statistics, and map on cancer mortality: Italy 1975-1977. Pitagora Ed. Bologna 1986. Cerca con Google

16. Blot WJ. Esophageal cancer trends and risk factors. Semin Oncol 1994; 21: 403-10. Cerca con Google

17. Blot W.J., McLaughlin J.K. The changing epidemiology of esophageal cancer. Sem. Oncol. 1999; 50: 6502-6507. Cerca con Google

18. D'Amico T.A., Harpole D.H. Molecular biology of esophageal cancer. Chest Surg. Clin. N. Am. 2000; 10: 451-469. Cerca con Google

19. Terry P., Lagergren J., Ye W., Nyren O., Wolk A. Antioxidant and cancers of the esophagus and gastric cardia. Int. J. cancer 2000; 87:750-4. Cerca con Google

20. Munoz N., Day N.E. Esophageal cancer. Cancer epidemiology and prevention. 2nd ed. Oxford University Press., New York 1996, pp 681-706 Cerca con Google

21. Negri E., La Vecchia C., Franceschi S. et al. Attribuable risk for esophageal cancer in Northern Italy. Eur J Cancer 1992; 28:1167-1171 Cerca con Google

22. Tuyns A.J., Pequignot G., Jensen O.M. Esophageal cancer in Ille-et-Villaine in relation to level of alcohol and tobacco consuption. Risk are moltiplying. Bull. Cancer 1977; 64: 45-60. Cerca con Google

23. Ashworth M.T., McDicken I.W., Southern S.A., Nash J.R. Human papillomavirus in squamous cell carcinoma of the oesophagus associated with tylosis. J. Clin. Pathol. 1993; 46:573-5. Cerca con Google

24. Cagol M., Bocus P., Ruol A., Ancona E. Endoscopic Ultrasonography and computed tomography in staging of carcinoma of the esophagus and gastric cardia Suppl. Tumori, 2004; 3: S5-S6 Cerca con Google

25. Collard J.M., Giuli R. Surgical and multimodal approaches to cancer of the esophagus: state of art. Acta Gastroenterologica Belgica 1999; 62: 272-282. Cerca con Google

26. Vallbahmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus. 2006;19:425-32. Cerca con Google

27. Tabernero J, Macarulla T, Ramos FJ, Baselga J. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol. 2005; 16:1740-8. Cerca con Google

28. Munck-Wikland E, Kuylenstierna R, Lindholm J, Wahren B. Carcinoembryonic antigen, CA 19-9, and CA 50 in monitoring human squamous cell carcinoma of the esophagus. Anticancer Res. 1990; 10:703-708. Cerca con Google

29. McKnight A, Mannell A, Shperling I. The role of carbohydrate antigen 19-9 as a tumor marker of oesophageal cancer. Br. J. Cancer 1989; 60:249-251. Cerca con Google

30. Clark GW, Ireland AP, Hagen JA, Collard JM, Peters JH, DeMeester TR. Carcinoembryonic antigen measurements in the management of esophageal cancer: an indicator of subclinical recurrence. Am. J. Surg. 1995; 170:597-600. Cerca con Google

31. Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer 1995; 75:451-456. Cerca con Google

32. Gion M, Tremolada C, Mione R, della Palma P, Dittami R, Zari C, Nosadini A, Castoro C, Ruol A, Peracchia A. Tumor markers in serum of patients with primary squamous cell carcinoma of the esophagus. Tumori 1989; 75:489-493. Cerca con Google

33. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977; 40:1621-1628. Cerca con Google

34. Hamada K, Shinomiya H, Asano Y, Kihana T, Iwamoto M, Hanakawa Y, Hashimoto K, Hirose S, Kyo S, Ito M. Molecular cloning of human squamous cell carcinoma antigen 1 gene and characterization of its promoter. Biochim Biophys Acta 2001; 1518:124-131. Cerca con Google

35. Pontisso P, Calabrese F, Benvegnù L, Lise M, Bellucco C, Rivoletto MG, De Falco S, Marino M, Valente M, Nitti D, Gatta A, Fassina G. Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. British Journal of Cancer. 2004; 90:833-837. Cerca con Google

36. Cataltepe S, Gornstein ER, Schick C, Kamachi Y, Chatson K, Fries J, Silverman GA, Upton MP. Co-expression of the squamous cell carcinoma antigen 1 and 2 in normal adult human tissues and squamous cell carcinoma. The journal of Histochemistry and Cytochemistry. 2000; 48: 113-122. Cerca con Google

37. Kato H. Squamous cell carcinoma antigen. Serological Cancer Markers. Sell S (ed). 1992; 437-451. Humana Press: Cifton. Cerca con Google

38. Kato H, Miyauchi F, Morioka H, Fujino T, Torigoe T. Tumor antigen of human cervical squamous cell carcinoma: correlation of circulating levels with disease progress. Cancer. 1979; 43:585-590. Cerca con Google

39. Mino N, Iio A, Hamamoto K. Avaiability of a tumor antigen TA-4 as a marker of squamous cell of the lung and other organs. Cancer. 1988; 62:730-734. Cerca con Google

40. Sugimachi K, Kitamura M, Matsuda H, Okudaira Y. Tumor antigen TA-4: an aid in detecting post-operative recurrences of esophageal carcinoma. Dis Markers 1987; 5:67-73. Cerca con Google

41. Mealy K, Feely J, Reid I, McSweeney J, Walsh T,Hennessy TPJ. Tumour marker detection in oesophageal carcinoma. European Journal of Surgical Oncology 1996; 22:505-507. Cerca con Google

42. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H, Ochiai T. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 2003; 133:486-494. Cerca con Google

43. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 22: 353 Cerca con Google

44. Castaldi F, Marino M, Beneduce L, Belluco C, De Marchi F, Mammano E, Nitti D, Lise M, Fassina G. Detection of circulating CEA-IgM complexes in early stage colorectal cancer. Int J Biol Markers. 2005; 20: 204-8 Cerca con Google

45. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Benvegnù L, Calabrese F, Gatta A, Pontisso P, Fassina G. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer. 2005; 103:2558-2565. Cerca con Google

46. Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E, Tono N, Fassina G, Cavalletto L, Gatta A, Chemello L. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer. 2006; 119:735-740. Cerca con Google

47. Beneduce L, Castaldi F, Marino M, Tono N, Gatta A, Pontisso P, Fassina G. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers. 2004; 19:155-159. Cerca con Google

48. Pontisso P, Calabrese F, Benvegnù L, Lise M, Belluco C, Ruvoletto MG, Marino M, Valente M, Nitti D, Gatta A, Fassina G. Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. Br J Cancer. 2004; 90: 833-7. Cerca con Google

49. Croce MV, Isla Larrain MT, Demichelis SO, Gori JR, Price MR, Segal-Eiras A. Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat. 2003; 81:195-207. Cerca con Google

50. Peyrat JP, Bonneter J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for loco-regional breast cancer. Lancet. 1995; 345:624-622. Cerca con Google

51. P.C. Enzinger and R.J. Mayer, Esophageal cancer. N Engl J Med 2003; 349: 2241-2252 Cerca con Google

52. V. Rasanen, E.I. Sihvo and M.J. Knuuti et al. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 2003; 10: 954-960. Cerca con Google

53. J.D. Luketich, D.M. Friedman and T.L. Weigel et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999; 68:1133-1136 Cerca con Google

54. J.D. Luketich, P. Schauer and R.J. Landreneau et al. Minimally invasive surgical staging is superior to endoscopic ultrasound in detecting lymph node metastases in esophageal cancer. J Thorac Cardiovasc Surg 1997; 114: 817-882. Cerca con Google

55. N. Kaushik, A. Khalid, D. Brody, J. Luketich and K. McGrath. Endoscopic ultrasound compared with laparoscopy for staging esophageal cancer. Ann Thorac Surg 2007; 83; 2000-2002. Cerca con Google

56. B.F. Meyers, R.J. Downey, P.A. Decker et al. and American College of Surgeons Oncology Group Z0060. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 2007; 133: 738-745. Cerca con Google

57. A. May, E. Günter, F. Roth, L. Gossner, M. Stolte, M. Vieth and C. Ell. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut 2004; 53: 634-640. Cerca con Google

58. J.D. Birkmeyer, A.E. Siewers and E.V. Finlayson et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137. Cerca con Google

59. A. Pennathur, R.J. Landreneau and J.D. Luketich. Surgical aspects of the patient with high-grade dysplasia. Semin Thorac Cardiovasc Surg 2005; 17: 326-332. Cerca con Google

60. J.B. Dimick, P.P. Goodney and M.B. Orringer et al. Specialty training and mortality after esophageal cancer resection. Ann Thorac Surg 2005; 80: 282-286 Cerca con Google

61. J.B. Dimick, P.J. Pronovost and R.E. Heitmiller et al. Intensive care unit staffing is associated with decreased length of stay, hospital cost, and complications after esophageal resection. Crit Care Med 2001; 29: 904-905. Cerca con Google

62. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3: 991-8. Cerca con Google

63. Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayouba A, Malanchère E, Coutinho A, Kazatchkine MD. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods. 1998; 216:117-37. Cerca con Google

64. Vollmers HP, Brändlein S. Natural antibodies and cancer. J Autoimmun. 2007; 29:295-302. Cerca con Google

65. Parenti A, Porzionato A, Pizzi S, Guzzardo V, Fascina G, Macchi V, Ninfo V, De Caro R. Expression pattern of squamous cell carcinoma antigen in oesophageal displasia and squamous cell carcinoma. Histol Histopatol 2007; 22:989-995 Cerca con Google

Solo per lo Staff dell Archivio: Modifica questo record